Literature DB >> 2521332

Left ventricular function and collagen content after regression of hypertensive hypertrophy.

W Motz1, B E Strauer.   

Abstract

To determine whether regression of hypertensive hypertrophy through blood pressure control also involves left ventricular collagen and consecutive alterations in left ventricular diastolic and systolic function, antihypertensive treatment with the calcium channel blocker nifedipine (30 mg/kg.day) was employed in 20-week-old spontaneously hypertensive rats (n = 15) for a period of 20 weeks. Age-matched (40 weeks old) untreated (n = 13) and 20-week-old spontaneously hypertensive rats representing the state before therapy (n = 14) were used for comparison. Myocardial stiffness was described by the tangent modulus Km of the elastic stiffness-stress relation. Left ventricular collagen was determined by means of hydroxyproline (OH-proline) concentration. Myocardial working capacity of the left ventricle was measured as the peak developed systolic pressure per weight unit muscle mass and systolic peak pump function as the maximum achievable cardiac output under volume loading. After the 20-week course of nifedipine treatment, systolic aortic pressure dropped from 187 +/- 11 to 144 +/- 6 mm Hg (p less than 0.001). Regression of hypertrophy was shown by a left ventricular muscle/body weight ratio of 2.13 +/- 0.18 mg/g (p less than 0.01) in the 40-week-old nifedipine-treated hypertensive rats, whereas the ratios of the 20-week-old and 40-week-old untreated spontaneously hypertensive rats were 2.3 +/- 0.30 and 2.34 +/- 0.18 mg/g, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521332     DOI: 10.1161/01.hyp.13.1.43

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.

Authors:  W Motz; B E Strauer
Journal:  Clin Investig       Date:  1992

2.  Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts.

Authors:  S C Tyagi; S E Campbell; H K Reddy; E Tjahja; D J Voelker
Journal:  Mol Cell Biochem       Date:  1996-02-09       Impact factor: 3.396

Review 3.  The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly.

Authors:  Craig R Butler; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 4.  Hypertension and age-related changes in the heart. Implications for drug therapy.

Authors:  S Isoyama
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

5.  Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation.

Authors:  Hanumanth K Reddy; Imam E Tjahja; Scott E Campbell; Joseph S Janicki; Melvin R Hayden; Suresh C Tyagi
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.